Who is sponsoring NCT06802809?

NCT06802809 is sponsored by Liaquat University of Medical & Health Sciences.

What drugs are being tested in NCT06802809?

Interventions in NCT06802809: Lactobacillus crispatus M247 (Crispact®), Placebo.

What condition does NCT06802809 study?

NCT06802809 studies Human Papillomavirus Infection.

Is NCT06802809 still recruiting?

NCT06802809 is currently completed. Last updated 4 June 2025.

Last reviewed 2025-06-04 · How we verify

NCT06802809

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Probiotic Lactobacillus Crispatus M247 in Promoting High-risk Human Papillomavirus (HR-HPV) Infection Clearance and Modifying Vaginal Microbiota

Completed NA Last updated 4 June 2025

What this trial tests

NA trial testing Lactobacillus crispatus M247 (Crispact®) in Human Papillomavirus Infection in 66 participants. Completed in 30 December 2024.

Timeline

5 January 2022

Primary endpoint
30 November 2024

30 December 2024

Quick facts

Lead sponsor	Liaquat University of Medical & Health Sciences
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	66
Start date	5 January 2022
Primary completion	30 November 2024
Estimated completion	30 December 2024
Sites	3 locations across Italy

Drugs / interventions tested

Lactobacillus crispatus M247 (Crispact®)
Placebo

Conditions studied

Human Papillomavirus Infection — all drugs for Human Papillomavirus Infection →

Sponsor

Liaquat University of Medical & Health Sciences

Who can join

Adults 18 to 69, female only, with Human Papillomavirus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial evaluates the efficacy of the probiotic strain Lactobacillus crispatus M247 in promoting the clearance of genital high-risk human papillomavirus (HR-HPV) infection and restoring the balance of the vaginal microbiota. The study adopts a multicenter, randomized, single-blind, longitudinal, prospective design involving HR-HPV-positive patients. Primary outcomes include HR-HPV clearance rates and microbiota composition changes.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Effect of orally administered L. crispatus M247 in favoring HR-HPV clearance and CST shift: results from a randomized, multi-center, placebo-controlled trial.
Di Pierro F, Sampugnaro EG, Lomeo GE, Guarneri MF, et al · · 2025 · cited 1× · PMID 41125728 · DOI 10.1038/s41598-025-20838-5
Harnessing the Power of Microbiota: How Do Key <i>Lactobacillus</i> Species Aid in Clearing High-Risk Human Papilloma Virus Infection and Promoting the Regression of Cervical Dysplasia?
Kęczkowska E, Wrotyńska-Barczyńska J, Bałabas A, Piątkowska M, et al · · 2025 · PMID 40906420 · DOI 10.3390/biology14081081

Verify or expand the search:

Other recruiting trials for Human Papillomavirus Infection

Currently open trials in the same condition.

NCT07281430 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04) · NA · recruiting
NCT06598475 — Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve · NA · recruiting
NCT06611553 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02) · NA · active not recruiting
NCT06611540 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03) · NA · active not recruiting
NCT06498661 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01) · NA · recruiting

Other Liaquat University of Medical & Health Sciences trials

Trials by the same sponsor.

NCT07519616 — Effect of Escherichia Coli 5C (Colipral®) on Post-Colonoscopy Gastrointestinal Symptoms · NA · not yet recruiting
NCT07536698 — Co-supplementation With Bifidobacterium Longum W11 and Colopectin for Maintenance Therapy in Children With Functional Co · NA · not yet recruiting
NCT07502807 — Effect of Neurofast® Supplementation on Anxiety and Cardiovascular Outcomes in the Psycho-Cardio Phenotype Adults · NA · not yet recruiting
NCT07494279 — Efficacy of Nigella Sativa (Nisatol®) in Women With Borderline Blood Pressure Values or a Non-Dipper Blood Pressure Phen · NA · not yet recruiting
NCT07474831 — Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial Vaginosis · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06802809 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Liaquat University of Medical & Health Sciences
Last refreshed: 4 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06802809.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing